Clinical usefulness of Somatostatin Receptor Scintigraphy in the Diagnosis of Neuroendocrine Neoplasms

Objective(s): We investigated the detectability of somatostatin receptor scintigraphy (SRS) for neuroendocrine neoplasms (NEN).Methods: From January ۲۰۱۶ to October ۲۰۲۰, ۱۲۵ SRS examinations using indium-۱۱۱ pentetreotide performed for patients with NEN lesions were retrospectively evaluated. The detection rate of NEN lesions was determined according to histopathological classification by primary site and by organ.Results: At least one NEN lesion was detected in ۷۳% (۹۱/۱۲۵) with a positive Krenning score of ≥۲ in SRS. The detection of abdominal NENs (gastrointestinal tract, ۳۸; pancreas, ۶۲; and others, ۱۴) was ۸۹% (۴۹/۵۵) for neuroendocrine tumor(NET)-grade (G) ۱, ۷۸% (۳۲/۴۱) for NET-G۲, ۶۶% (۲/۳) for NET-G۳, ۳۱% (۴/۱۳) for neuroendocrine carcinoma (NEC), ۱۰۰% (۱/۱) for mixed neuroendocrine–nonneuroendocrine neoplasm, and ۰% (۰/۱) for non-classified NEN. That of thoracic NENs was ۳۳% (۲/۶) for typical carcinoid tumor and ۴۰% (۲/۵) for atypical carcinoid tumor. For a total of ۲۲۶ organ lesions, hepatic lesions were ۷۶% (۵۸/۷۶); pancreatic lesions, ۶۱% (۳۱/۵۱); lymph node lesions, ۷۷% (۲۷/۳۵); bone lesions, ۸۳% (۲۰/۲۴); duodenal lesions, ۸۲% (۹/۱۱); and other lesions, ۴۱% (۱۱/۲۷).Conclusion: The detectability of SRS for NEN in Japan was verified at a center, and its usefulness was confirmed.

Keywords:

neuroendocrine neoplasms (NEN) , Neuroendocrine Tumor (NET) , somatostatin receptor scintigraphy (SRS) , Indium-۱۱۱ pentetreotide Octreo scan